Clinical Trial Update: Brentuximab Vedotin and Chemotherapy in CD30+ PMBL, Diffuse Large B-Cell, and Grey Zone Lymphoma Patients [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study evaluating brentuximab vedotin with chemotherapy in CD30+ primary mediastinal large B-cell lymphoma, CD30+ diffuse large B-cell lymphoma, and CD…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Gray Zone Lymphoma
• Mediastinal Large B-cell Lymphoma

Drugs mentioned

• Brentuximab vedotin (Brentuximab vedotin)

Snippet

Sponsor: Abramson Cancer Center at Penn Medicine | Conditions: CD30 Positive Primary Mediastinal Large B-cell Lymphoma, CD30-Positive Diffuse Large B-Cell Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-09-17